View in EDS

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor.

Saved in:
Bibliographic Details
Title: Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor.
Authors: Heinrich MC; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland., Corless CL; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland., Demetri GD; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland., Blanke CD; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland., von Mehren M; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland., Joensuu H; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland., McGreevey LS; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland., Chen CJ; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland., Van den Abbeele AD; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland., Druker BJ; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland., Kiese B; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland., Eisenberg B; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland., Roberts PJ; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland., Singer S; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland., Fletcher CDM; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland., Silberman S; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland., Dimitrijevic S; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland., Fletcher JA; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Nov 01; Vol. 41 (31), pp. 4829-4836.
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE; PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37890277
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Heinrich+MC%22">Heinrich MC</searchLink>; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Corless+CL%22">Corless CL</searchLink>; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Demetri+GD%22">Demetri GD</searchLink>; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Blanke+CD%22">Blanke CD</searchLink>; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22von+Mehren+M%22">von Mehren M</searchLink>; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Joensuu+H%22">Joensuu H</searchLink>; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22McGreevey+LS%22">McGreevey LS</searchLink>; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Chen+CJ%22">Chen CJ</searchLink>; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Van+den+Abbeele+AD%22">Van den Abbeele AD</searchLink>; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Druker+BJ%22">Druker BJ</searchLink>; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kiese+B%22">Kiese B</searchLink>; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Eisenberg+B%22">Eisenberg B</searchLink>; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Roberts+PJ%22">Roberts PJ</searchLink>; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Singer+S%22">Singer S</searchLink>; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Fletcher+CDM%22">Fletcher CDM</searchLink>; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Silberman+S%22">Silberman S</searchLink>; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Dimitrijevic+S%22">Dimitrijevic S</searchLink>; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Fletcher+JA%22">Fletcher JA</searchLink>; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309333%22">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</searchLink> [J Clin Oncol] 2023 Nov 01; Vol. 41 (31), pp. 4829-4836.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309333 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1527-7755 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220732183X%22">0732183X </searchLink><i>NLM ISO Abbreviation: </i>J Clin Oncol <i>Subsets: </i>MEDLINE; PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37890277
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/JCO.22.02771
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 4829
    Titles:
      – TitleFull: Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Heinrich MC
      – PersonEntity:
          Name:
            NameFull: Corless CL
      – PersonEntity:
          Name:
            NameFull: Demetri GD
      – PersonEntity:
          Name:
            NameFull: Blanke CD
      – PersonEntity:
          Name:
            NameFull: von Mehren M
      – PersonEntity:
          Name:
            NameFull: Joensuu H
      – PersonEntity:
          Name:
            NameFull: McGreevey LS
      – PersonEntity:
          Name:
            NameFull: Chen CJ
      – PersonEntity:
          Name:
            NameFull: Van den Abbeele AD
      – PersonEntity:
          Name:
            NameFull: Druker BJ
      – PersonEntity:
          Name:
            NameFull: Kiese B
      – PersonEntity:
          Name:
            NameFull: Eisenberg B
      – PersonEntity:
          Name:
            NameFull: Roberts PJ
      – PersonEntity:
          Name:
            NameFull: Singer S
      – PersonEntity:
          Name:
            NameFull: Fletcher CDM
      – PersonEntity:
          Name:
            NameFull: Silberman S
      – PersonEntity:
          Name:
            NameFull: Dimitrijevic S
      – PersonEntity:
          Name:
            NameFull: Fletcher JA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2023 Nov 01
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1527-7755
          Numbering:
            – Type: volume
              Value: 41
            – Type: issue
              Value: 31
          Titles:
            – TitleFull: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
              Type: main
ResultId 1